

# Naoto Hirano

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9576160/publications.pdf>

Version: 2024-02-01

100  
papers

4,367  
citations

147726

31  
h-index

110317

64  
g-index

102  
all docs

102  
docs citations

102  
times ranked

6306  
citing authors

#	ARTICLE	IF	CITATIONS
1	Characterization of Proteasome-Generated Spliced Peptides Detected by Mass Spectrometry. <i>Journal of Immunology</i> , 2022, 208, 2856-2865.	0.4	1
2	Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy. <i>Nature Immunology</i> , 2022, 23, 1273-1283.	7.0	17
3	Changing the landscape of tumor immunology: novel tools to examine T cell specificity. <i>Current Opinion in Immunology</i> , 2021, 69, 1-9.	2.4	2
4	Affinity-matured HLA class II dimers for robust staining of antigen-specific CD4+ T cells. <i>Nature Biotechnology</i> , 2021, 39, 958-967.	9.4	15
5	Heterogeneity of Circulating Tumor Cell-Associated Genomic Gains in Breast Cancer and Its Association with the Host Immune Response. <i>Cancer Research</i> , 2021, 81, 6196-6206.	0.4	5
6	Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy. <i>Cancer Immunology Research</i> , 2020, 8, 926-936.	1.6	73
7	Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma. <i>ELife</i> , 2020, 9, .	2.8	13
8	129-...A novel CAR conducting antigen-specific JAK-STAT signals demonstrates superior antitumor effects with minimal undesired non-specific activation. , 2020, , .		0
9	Adoptive T cell therapy with TBI-1301 results in gene-engineered T cell persistence and anti-tumour responses in patients with NY-ESO-1 expressing solid tumours. <i>Annals of Oncology</i> , 2019, 30, v481.	0.6	7
10	Validation of CyTOF Against Flow Cytometry for Immunological Studies and Monitoring of Human Cancer Clinical Trials. <i>Frontiers in Oncology</i> , 2019, 9, 415.	1.3	114
11	Chaperones of the class I peptide-loading complex facilitate the constitutive presentation of endogenous antigens on HLA-DP84CGPM87. <i>Journal of Autoimmunity</i> , 2019, 102, 114-125.	3.0	2
12	Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 773-785.	2.0	94
13	In vitro -generated MART -specific CD 8 T cells display a broader T-cell receptor repertoire than ex vivo na-ve and tumor-infiltrating lymphocytes. <i>Immunology and Cell Biology</i> , 2019, 97, 427-434.	1.0	0
14	Arginine methylation of FOXP3 is crucial for the suppressive function of regulatory T cells. <i>Journal of Autoimmunity</i> , 2019, 97, 10-21.	3.0	34
15	Gene Modification and Immunological Analyses for the Development of Immunotherapy Utilizing T Cells Redirected with Antigen-Specific Receptors. <i>Methods in Molecular Biology</i> , 2019, 2048, 27-39.	0.4	0
16	Effect of minimal lymphodepletion prior to ACT with TBI-1301, NY-ESO-1 specific gene-engineered TCR-T cells, on clinical responses and CRS.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2537-2537.	0.8	4
17	Abstract 568: Decoding shared antigenic epitopes and their cognate TCR genes in melanoma TILs using a library of paired human cell-based pHLA multimers and artificial APCs. , 2019, , .		2
18	Abstract 568: Decoding shared antigenic epitopes and their cognate TCR genes in melanoma TILs using a library of paired human cell-based pHLA multimers and artificial APCs. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
19	MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection. <i>Journal of Proteomics</i> , 2018, 176, 13-23.	1.2	27
20	A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. <i>Nature Medicine</i> , 2018, 24, 352-359.	15.2	349
21	A Subset of Human Autoreactive CD1c-Restricted T Cells Preferentially Expresses TRBV4-1+ TCRs. <i>Journal of Immunology</i> , 2018, 200, 500-511.	0.4	17
22	Mechanisms underlying the lack of endogenous processing and CLIP-mediated binding of the invariant chain by HLA-DP84Gly. <i>Scientific Reports</i> , 2018, 8, 4804.	1.6	8
23	Mechanisms of HLA-DP Antigen Processing and Presentation Revisited. <i>Trends in Immunology</i> , 2018, 39, 960-964.	2.9	16
24	Study of TBI-1301 (NY-ESO-1 specific TCR gene transduced autologous T lymphocytes) in patients with solid tumors. <i>Annals of Oncology</i> , 2018, 29, viii441.	0.6	1
25	Generation and molecular recognition of melanoma-associated antigen-specific human $\alpha\beta$ T cells. <i>Science Immunology</i> , 2018, 3, .	5.6	43
26	CapTCR-seq: hybrid capture for T-cell receptor repertoire profiling. <i>Blood Advances</i> , 2018, 2, 3506-3514.	2.5	18
27	DOT1L inhibition attenuates graft-versus-host disease by allogeneic T cells in adoptive immunotherapy models. <i>Nature Communications</i> , 2018, 9, 1915.	5.8	21
28	Two Weeks' Notice from Allogeneic Sources. <i>Clinical Cancer Research</i> , 2018, 24, 5195-5197.	3.2	1
29	Infusion of <i>ex-vivo</i> expanded human TCR $\alpha\beta$ + double-negative regulatory T cells delays onset of xenogeneic graft-versus-host disease. <i>Clinical and Experimental Immunology</i> , 2018, 193, 386-399.	1.1	19
30	Type I interferon responses drive intrahepatic T cells to promote metabolic syndrome. <i>Science Immunology</i> , 2017, 2, .	5.6	135
31	HLA-DP84Gly constitutively presents endogenous peptides generated by the class I antigen processing pathway. <i>Nature Communications</i> , 2017, 8, 15244.	5.8	28
32	Key Residues at Third CDR3 $\beta$ Position Impact Structure and Antigen Recognition of Human Invariant NK TCRs. <i>Journal of Immunology</i> , 2017, 198, 1056-1065.	0.4	3
33	Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1054-1066.	2.9	130
34	Transient stimulation expands superior antitumor T cells for adoptive therapy. <i>JCI Insight</i> , 2017, 2, e89580.	2.3	37
35	Abstract PR09: A novel chimeric antigen receptor containing JAK-STAT signaling domains mediates superior antitumor effects. , 2017, , .		0
36	Mouse and Human CD1d-Self-Lipid Complexes Are Recognized Differently by Murine Invariant Natural Killer T Cell Receptors. <i>PLoS ONE</i> , 2016, 11, e0156114.	1.1	3

#	ARTICLE	IF	CITATIONS
37	CD4+ and CD8+ TCR $\beta$ repertoires possess different potentials to generate extraordinarily high-avidity T cells. <i>Scientific Reports</i> , 2016, 6, 23821.	1.6	13
38	Generating <em>De Novo</em> Antigen-specific Human T Cell Receptors by Retroviral Transduction of Centric Hemichain. <i>Journal of Visualized Experiments</i> , 2016, , .	0.2	2
39	CDR3 $\beta$ sequence motifs regulate autoreactivity of human invariant NKT cell receptors. <i>Journal of Autoimmunity</i> , 2016, 68, 39-51.	3.0	12
40	BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models. <i>Journal of Clinical Investigation</i> , 2016, 126, 3479-3494.	3.9	168
41	2015 Guidance on cancer immunotherapy development in earlyâ€phase clinical studies. <i>Cancer Science</i> , 2015, 106, 1761-1771.	1.7	16
42	Adoptive T Cell Therapy Targeting CD1 and MR1. <i>Frontiers in Immunology</i> , 2015, 6, 247.	2.2	15
43	Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy. <i>Cancer Immunology Research</i> , 2015, 3, 1070-1081.	1.6	29
44	Specific Roles of Each TCR Hemichain in Generating Functional Chain-Centric TCR. <i>Journal of Immunology</i> , 2015, 194, 3487-3500.	0.4	35
45	Human cellâ€based artificial antigenâ€presenting cells for cancer immunotherapy. <i>Immunological Reviews</i> , 2014, 257, 191-209.	2.8	96
46	A clinical grade cell-based artificial APT, aAPC/mOIK3, for unbiased expansion of CD3+ T lymphocytes. , 2014, 2, P5.		0
47	IL-21 Can Supplement Suboptimal Lck-Independent MAPK Activation in a STAT-3â€Dependent Manner in Human CD8+ T Cells. <i>Journal of Immunology</i> , 2012, 188, 1609-1619.	0.4	10
48	Ex Vivo Expansion of Human CD8+ T Cells Using Autologous CD4+ T Cell Help. <i>PLoS ONE</i> , 2012, 7, e30229.	1.1	31
49	Establishment of Antitumor Memory in Humans Using in Vitroâ€Educated CD8 <sup>+</sup> T Cells. <i>Science Translational Medicine</i> , 2011, 3, 80ra34.	5.8	94
50	The Third Consensus Conference on the treatment of aplastic anemia. <i>International Journal of Hematology</i> , 2011, 93, 832-837.	0.7	17
51	Induction of HLA-DP4â€Restricted Anti-Survivin Th1 and Th2 Responses Using an Artificial Antigen-Presenting Cell. <i>Clinical Cancer Research</i> , 2011, 17, 5392-5401.	3.2	24
52	Endogenous Ligands Selectively Stimulate Highly Avid Autoreactive Human Invariant Natural Killer T Cells with Distinctive T-Cell Receptor V $\beta$ 11 CDR3 Sequence Motifs. <i>Blood</i> , 2011, 118, 999-999.	0.6	1
53	A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4+ T cells restricted by prevalent HLA-DR alleles. <i>International Immunology</i> , 2010, 22, 863-873.	1.8	39
54	Juvenile Myelomonocytic Leukemia. <i>Paediatric Drugs</i> , 2010, 12, 11-21.	1.3	23

#	ARTICLE	IF	CITATIONS
55	CD8 Coreceptor-Independent T Cell Stimulation Induces High Avidity CTL In the Presence of IL-21. <i>Blood</i> , 2010, 116, 2086-2086.	0.6	0
56	Efficient Generation of HLA-A24-Restricted WT1-Specific Cytotoxic T Lymphocytes Using Gene-Engineered Artificial Antigen-Presenting Cells. <i>Blood</i> , 2010, 116, 2101-2101.	0.6	0
57	Human CD4+ T Cells Help CD8+ T Cells Proliferate Ex Vivo by Secreting Both IL-2/IL-21 and Upregulating IL-21R. <i>Blood</i> , 2010, 116, 4284-4284.	0.6	3
58	A Series of Human Cell-Based Artificial APC Expands Long-Lived, Th1-Biased, Viral Antigen-Specific CD4+ T Cells with a Central/Effector Memory Phenotype Restricted by Common HLA-DR Alleles. <i>Blood</i> , 2010, 116, 354-354.	0.6	83
59	Establishing CD8+ T Cell Immunity by Adoptive Transfer of Autologous, IL-15 Expanded, Anti-Tumor CTL with a Central/Effector Memory Phenotype Can Induce Objective Clinical Responses.. <i>Blood</i> , 2009, 114, 782-782.	0.6	1
60	Immunogenicity of Artificial Dendritic Cells Is Upregulated by ROCK Inhibition-Mediated Dendrite Formation.. <i>Blood</i> , 2009, 114, 3022-3022.	0.6	0
61	Artificial APC-Based Generation of IL-21 Secreting CD4+ T Cells That Can Provide Help to CD8+ T Cells.. <i>Blood</i> , 2009, 114, 466-466.	0.6	0
62	Clinical impact of HLA-DR15, a minor population of paroxysmal nocturnal haemoglobinuria-type cells, and an aplastic anaemia-associated autoantibody in children with acquired aplastic anaemia. <i>British Journal of Haematology</i> , 2008, 142, 427-435.	1.2	48
63	Dissociation of Its Opposing Immunologic Effects Is Critical for the Optimization of Antitumor CD8+ T-Cell Responses Induced by Interleukin 21. <i>Clinical Cancer Research</i> , 2008, 14, 6125-6136.	3.2	18
64	Long-Lived Antitumor CD8+ Lymphocytes for Adoptive Therapy Generated Using an Artificial Antigen-Presenting Cell. <i>Clinical Cancer Research</i> , 2007, 13, 1857-1867.	3.2	123
65	Identification of an immunogenic CD8+ T-cell epitope derived from $\beta$ -globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia. <i>Blood</i> , 2006, 108, 2662-2668.	0.6	19
66	Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity. <i>Blood</i> , 2006, 107, 1528-1536.	0.6	156
67	Efficient Presentation of Naturally Processed HLA Class I Peptides by Artificial Antigen-Presenting Cells for the Generation of Effective Antitumor Responses. <i>Clinical Cancer Research</i> , 2006, 12, 2967-2975.	3.2	38
68	Presence of HLA-DR15, a Minor PNH Clone, or an Aplastic Anemia - Associated Autoantibody Do Not Predict a Favorable Response to Immunosuppressive Therapy in Children with Aplastic Anemia.. <i>Blood</i> , 2006, 108, 984-984.	0.6	1
69	Presence of anti-kinectin and anti-PMS1 antibodies in Japanese aplastic anaemia patients. <i>British Journal of Haematology</i> , 2005, 128, 221-223.	1.2	30
70	4-1BB (CD137) or CD40 Signaling Fails To Improve the Expansion of Antigen Specific T Cells Demonstrated with Engagement of TCR, CD28 and CD83 Ligand.. <i>Blood</i> , 2004, 104, 2665-2665.	0.6	2
71	Off the Shelf, GMP Grade Artificial APC Efficiently Generates Large Numbers of Antigen Specific CTLs Sufficient for the Treatment of Cancer and Infectious Disease.. <i>Blood</i> , 2004, 104, 3172-3172.	0.6	0
72	Highly Efficient Presentation of Endogenously Processed Class I Peptides by Artificial APC for the Generation of Effective Anti-Tumor Responses.. <i>Blood</i> , 2004, 104, 1355-1355.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Î³-Globin, a Tumor-Associated Antigen for Juvenile Myelomonocytic Leukemia (JMML): A Cell-Based Approach To Identify Tumor Antigenic Epitopes That Are Naturally Processed and Presented.. Blood, 2004, 104, 3418-3418.	0.6	0
74	Autoantibodies frequently detected in patients with aplastic anemia. Blood, 2003, 102, 4567-4575.	0.6	105
75	The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood, 2003, 102, 3287-3294.	0.6	77
76	Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood, 2002, 99, 3319-3325.	0.6	177
77	Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells. Nature Immunology, 2001, 2, 1174-1182.	7.0	250
78	CD40 activation of carcinoma cells increases expression of adhesion and major histocompatibility molecules but fails to induce either CD80/CD86 expression or T cell alloreactivity. International Journal of Oncology, 2001, 19, 791-8.	1.4	4
79	Immunogene therapy against mouse leukemia using B7 molecules. Cancer Gene Therapy, 2000, 7, 144-150.	2.2	12
80	CIZ, a Zinc Finger Protein That Interacts with p130 cas and Activates the Expression of Matrix Metalloproteinases. Molecular and Cellular Biology, 2000, 20, 1649-1658.	1.1	116
81	Spontaneous Remission in Acute Type Adult T-Cell Leukemia/Lymphoma. Leukemia and Lymphoma, 2000, 39, 217-222.	0.6	7
82	Transplantation of Anergic Histoincompatible Bone Marrow Allografts. New England Journal of Medicine, 1999, 340, 1704-1714.	13.9	428
83	A Potential Molecular Approach to Ex Vivo Hematopoietic Expansion With Recombinant Epidermal Growth Factor Receptor-Expressing Adenovirus Vector. Blood, 1998, 91, 4509-4515.	0.6	26
84	A rare atypical myeloproliferative-disorder-like hemopathy with marked dysplasia, peripheral dominant myeloblast proliferation and extramedullary hematopoiesis was converted into typical acute myeloid leukemia with an interval of complete hematological remission. International Journal of Hematology, 1998, 67, 411.	0.7	2
85	Protective and Therapeutic Immunity Against Leukemia Induced by Irradiated B7-1 (CD80)-Transduced Leukemic Cells. Human Gene Therapy, 1997, 8, 1375-1384.	1.4	29
86	Rapid progression of chronic myelomonocytic leukemia following diaminodiphenyl sulphone treatment for dermatitis herpetiformis. International Journal of Hematology, 1997, 66, 383.	0.7	1
87	Protective and therapeutic immunity against leukemia induced by irradiated B7-1 (CD80)-transduced leukemic cells. Leukemia, 1997, 11 Suppl 3, 577-81.	3.3	0
88	A Conserved Cysteine Residue in the runt Homology Domain of AML1 Is Required for the DNA Binding Ability and the Transforming Activity on Fibroblasts. Journal of Biological Chemistry, 1996, 271, 16870-16876.	1.6	40
89	Expression of costimulatory molecules in human leukemias. Leukemia, 1996, 10, 1168-76.	3.3	103
90	Of the GATA-Binding Proteins, Only GATA-4 Selectively Regulates the Human Interleukin-5 Gene Promoter in Interleukin-5-Producing Cells Which Express multiple GATA-Binding Proteins. Molecular and Cellular Biology, 1995, 15, 3830-3839.	1.1	84

#	ARTICLE	IF	CITATIONS
91	Molecular Cloning of the Human Glucose-Regulated Protein ERp57/GRP58, a Thiol-Dependent Reductase. Identification of its Secretory form and Inducible Expression by the Oncogenic Transformation. FEBS Journal, 1995, 234, 336-342.	0.2	121
92	Characterization of three erythropoietin (Epo)-binding proteins in various human Epo-responsive cell lines and in cells transfected with human Epo-receptor cDNA [see comments]. Blood, 1995, 85, 106-114.	0.6	13
93	An Epidermal Growth Factor Receptor-Leukocyte Tyrosine Kinase Chimeric Receptor Generates Ligand-dependent Growth Signals through the Ras Signaling Pathway. Journal of Biological Chemistry, 1995, 270, 20135-20142.	1.6	31
94	Homozygous loss of the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemias. Blood, 1994, 84, 2431-2435.	0.6	166
95	Molecular Cloning and Characterization of a cDNA for Bovine Phospholipase C- $\beta$ : Proposal of Redesignation of Phospholipase C- $\beta$ . Biochemical and Biophysical Research Communications, 1994, 204, 375-382.	1.0	29
96	Homozygous loss of the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemias. Blood, 1994, 84, 2431-2435.	0.6	6
97	Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS- derived leukemia. Blood, 1993, 81, 3022-3026.	0.6	118
98	Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS- derived leukemia. Blood, 1993, 81, 3022-3026.	0.6	1
99	Analysis of Rabbit Intervertebral Disc Physiology Based on Water Metabolism. Spine, 1988, 13, 1291-1296.	1.0	14
100	Analysis of Rabbit Intervertebral Disc Physiology Based on Water Metabolism. Spine, 1988, 13, 1297-1302.	1.0	20